27.01.2022 | Knee Arthroplasty
Constraint in complex primary total knee arthroplasty: rotating hinge versus condylar constrained implants
verfasst von:
Francesco Castagnini, Barbara Bordini, Monica Cosentino, Cristina Ancarani, Stefano Lucchini, Giovanni Bracci, Francesco Traina
Erschienen in:
Archives of Orthopaedic and Trauma Surgery
|
Ausgabe 12/2022
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Condylar constrained knee arthroplasties (CCKAs) and rotating hinge knee arthroplasties (RHKAs) achieved good outcomes in complex primary total knee arthroplasties (TKAs); however, long-term comparative studies are few. Using an arthroplasty registry, we sought to assess and compare in CCKAs and RHKAs: (1) the intra-operative rates of complications, (2) the survival rates, (3) the reasons for revision, and (4) the adjusted hazard ratios for failure.
Materials and methods
1432 constrained implants in primary TKAs performed for non-oncological indications were included: 703 RHKAs, 729 CCKAs. The two groups were comparable regarding age and gender. Kaplan–Meier curves were used to compare survival rates, multivariate analyses to assess the hazard ratios for failures.
Results
The mean follow-up was 4.1 years (range 0–16.3) for CCKAs and 6.8 years (0–18.1) for RHKAs. The intra/peri-operative complications were similar in both the cohorts, with similar rates of femoral and tibial fractures. 10-year implant survival rates were similar in both the cohorts (91.9%, CI 95% 89.2–93.9% in RHKAs; 93.4%, CI 95% 90.3–95.6% in CCKAs). Periprosthetic infection was the most common reason for revision in the two cohorts, followed by aseptic loosening. Breakage occurred in 3 RHKAs (0.4%). CCKAs and RHKAs had a similar distribution of revision causes. Males aged less than 60 had significantly more failures, regardless the constraint degree. Unstemmed CCKAs significantly failed more than RHKAs and stemmed CCKAs.
Conclusions
Both modern CCKAs and RHKAs are viable long-term solutions in complex primary TKAs. More failures should be expected in males aged less than 60.
Level of evidence
IV, Therapeutic study.